Research ArticleTheranostics
PET Using a GRPR Antagonist 68Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients
Jingjing Zhang, Gang Niu, Xinrong Fan, Lixin Lang, Guozhu Hou, Libo Chen, Huanwen Wu, Zhaohui Zhu, Fang Li and Xiaoyuan Chen
Journal of Nuclear Medicine June 2018, 59 (6) 922-928; DOI: https://doi.org/10.2967/jnumed.117.198929
Jingjing Zhang
1Department of Nuclear Medicine, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Science & PUMC, Beijing, China
2Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
3Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, Maryland
Gang Niu
3Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, Maryland
Xinrong Fan
4Department of Urology, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Science & PUMC, Beijing, China; and
Lixin Lang
3Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, Maryland
Guozhu Hou
1Department of Nuclear Medicine, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Science & PUMC, Beijing, China
2Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
Libo Chen
1Department of Nuclear Medicine, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Science & PUMC, Beijing, China
2Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
Huanwen Wu
5Department of Pathology, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Science & PUMC, Beijing, China
Zhaohui Zhu
1Department of Nuclear Medicine, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Science & PUMC, Beijing, China
2Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
Fang Li
1Department of Nuclear Medicine, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Science & PUMC, Beijing, China
2Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China
Xiaoyuan Chen
3Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, Maryland
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 59, Issue 6
June 1, 2018
PET Using a GRPR Antagonist 68Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients
Jingjing Zhang, Gang Niu, Xinrong Fan, Lixin Lang, Guozhu Hou, Libo Chen, Huanwen Wu, Zhaohui Zhu, Fang Li, Xiaoyuan Chen
Journal of Nuclear Medicine Jun 2018, 59 (6) 922-928; DOI: 10.2967/jnumed.117.198929
Jump to section
Related Articles
Cited By...
- Comparison of 68Ga-PSMA-617 PET/CT and 68Ga-RM2 PET/CT in Patients with Localized Prostate Cancer Who Are Candidates for Radical Prostatectomy: A Prospective, Single-Arm, Single-Center, Phase II Study
- Clinical Translation of a 68Ga-Labeled Integrin {alpha}v{beta}6-Targeting Cyclic Radiotracer for PET Imaging of Pancreatic Cancer
- Imaging the Distribution of Gastrin-Releasing Peptide Receptors in Cancer